CheckMate 816试验：非小细胞肺癌新辅助化疗免疫疗法的一个里程碑。
The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer.
作者信息
Mayenga Marie, Pedroso Ana Rita, Ferreira Marion, Gille Thomas, Pereira Catarata Maria Joana, Duchemann Boris
机构信息
Department of Pulmonology, Foch Hospital, Suresnes, France.
Pulmonology Department, Local Health Unit of Braga, Braga, Portugal.
出版信息
Breathe (Sheff). 2024 Nov 12;20(3):240044. doi: 10.1183/20734735.0044-2024. eCollection 2024 Oct.
Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemotherapy compared with chemotherapy alone. Furthermore, this article discusses the implications for future practice in resectable NSCLC and the need for future research.
围手术期免疫治疗的进展彻底改变了可切除非小细胞肺癌（NSCLC）的治疗方式。在此，我们介绍了CheckMate 816临床试验的方法和结果，该试验证明了与单纯化疗相比，纳武利尤单抗联合化疗进行新辅助治疗的益处。此外，本文还讨论了其对可切除NSCLC未来临床实践的影响以及未来研究的必要性。
Zotero 插件